November 10, 2017 07:59 AM EST

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte

John Carroll

Editor & Founder

WASHINGTON, DC — While Incyte and the founders of Flexus scrap in court over who owns the IDO1 technology that Bristol-Myers Squibb $BMY bought in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte

John Carroll

Editor & Founder

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer

Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug

Corrected: Merck opens billion-dollar US facility to make Gardasil

Obesity drug development—still room to grow

Bris­tol-My­ers of­fers a pos­i­tive snap­shot on ear­ly da­ta for an IDO1 ri­val to In­cyte

Editor & Founder

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte